Live Breaking News & Updates on Conference on vaccinology research

Stay updated with breaking news from Conference on vaccinology research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Underrepresented populations, those with lower income at higher risk for severe RSV

Underrepresented populations, those with lower income at higher risk for severe RSV
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Emilyk-horn , Kate-kanaby , William-schaffner , Richard-smith , Conference-on-vaccinology-research , Nutrition-examination , National-health , Advisory-committee-on-immunization-practices , Immunization-practices , Vaccinology-research

NFID Celebrates 50th Anniversary with Gala Honoring Public Health Heroes

Today marks the 50th anniversary of the establishment of the National Foundation for Infectious Diseases (NFID) which will be commemorated with an elegant 50th Anniversary Gala in Washington, DC on September 14, 2023. Celebrating 50 years of education, prevention, and impact, the gala will recognize the work of NFID and the inspirational public health heroes who have helped protect the lives of millions.

Washington , United-states , Virginia , Diana-olson , Johnp-utz , William-schaffner , Roberth-hopkins-jr , Patricia-patsya-stinchfield , Richardj-duma , Marla-dalton , Waltera-orenstein , National-institutes-of-health

Dynavax Technologies (DVAX) Q2 2023 Earnings Call Transcript

DVAX earnings call for the period ending June 30, 2023.

Germany , Ernesto-rodriguez-dumont-cowen , Jon-miller , Dynavax-technologie , Jonathan-miller-evercore , Donn-casale , Matthew-phipps , Matthew-phipps-william-blair , William-blair , Kelly-macdonald , Ernesto-rodriguez-dumont , Rob-janssen

Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2023 Earnings Call Transcript

Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2023 Earnings Call Transcript August 3, 2023 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.03 EPS, expectations were $0.09. Operator: Good day ladies and gentlemen, and welcome to Dynavax Technologies’ Second Quarter 2023 Financial Results. As a reminder, this conference is being recorded. At the end of […]

Donn-casale , Rob-janssen , Kelly-macdonald , Us-department-of-defense , Conference-on-vaccinology-research , Department-of-defense , Scientific-advisory-board , Most-craft-breweries , Growth-stocks-under , Dynavax-technologies-corporation , Epatitisb-vaccine , Arket-share

Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2023 Earnings Call Transcript

Operator: Good day ladies and gentlemen. And welcome to Dynavax Technologies' First Quarter 2023 Financial Results Conference Call. As a reminder, this conference is being recorded.

China , United-kingdom , India , Germany , Great-britain , Madhu-kumar , Ryan-spencer , Rob-janssen , Joshua-schimmer , Paul-cox , Phil-nadeau , Ernie-rodriguez

Dynavax Technologies (DVAX) Q1 2023 Earnings Call Transcript

DVAX earnings call for the period ending March 31, 2023.

United-kingdom , India , Germany , China , Great-britain , Roy-buchanan , Madhu-kumar , Josh-schimmer , Josh-schimmer-evercore , Matthew-phipps , Dynavax-technologie , William-blair

Dynavax Reports First Quarter 2023 Financial Results

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

United-kingdom , India , Great-britain , Ryan-spencer , Paul-cox , Nicole-arndt , Twitter , Prnewswire-dynavax-technologies-corporation-nasdaq , Securities-exchange , European-union , Prevention-advisory-committee-of-immunization-practices , Us-department-of-defense

Dynavax Reports First Quarter 2023 Financial Results

Dynavax Reports First Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

India , United-kingdom , Great-britain , Ryan-spencer , Paul-cox , Nicole-arndt , Centers-for-disease , Regulatory-agency , National-foundation-for-infectious-disease , Delivery-networks-idns , Prnewswire-dynavax-technologies-corporation-nasdaq , Company-cp

Association Between 2-Dose vs 3-Dose Hepatitis B Vaccine and Acute Myocardial Infarction

This large prospective cohort study compares the rates of acute myocardial infarction between recipients of a 2-dose hepatitis B vaccine and recipients of a 3-d

California , United-states , Katia-bruxvoort , Jennifer-nelson , Nidia-golla , Brittany-brown , Kimberly-erby , Nigel-gupta , Randall-hyer , Arthur-reingold , Karen-schenk , Mingsum-lee

Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results

Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results
News provided by
Share this article
Share this article
PRINCETON, N.J., May 17, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2021.
"This year continues to be an exciting year of progress for Soligenix," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "We recently announced presentation of clinical data from our successful pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) clinical trial for HyBryte™ (SGX301) in the treatment of cutaneous T-cell lymphoma (CTCL) at both the American Academy of Dermatology, where HyBryte™ was designated "Top 12 late-breaking research," and the Society for Investigative Dermatology. We also received U.S. Food and Drug Administration (FDA) conditional acceptance of HyBryte™ as the proposed brand name for SGX301 (synthetic hypericin), as we continue to prepare for a new drug application (NDA) submission and U.S. commercialization for this novel first-in-class photodynamic therapy for treatment of early stage CTCL. Under our Public Health Solutions business segment, supported by non-dilutive government funding, we continue to advance multiple therapeutic and vaccine candidates. CiVax™, our heat stable COVID-19 vaccine, recently demonstrated that the proprietary subunit protein antigen, locked into its receptor-binding configuration, was immunogenic in both mice and non-human primates, which is an important step in advancing CiVax™ towards human clinical trials."

United-states , United-kingdom , American , Ellen-kim , Christopherj-schaber , Oreola-donini , Us-congress , National-institute-of-allergy , American-academy-of-dermatology-association-virtual-meeting , Nasdaq , American-academy-of-dermatology , Soligenix-inc